From: A robust blood gene expression-based prognostic model for castration-resistant prostate cancer
A. Univariate analysis of validation set II | Â | Â | Â |
---|---|---|---|
 | Concordance index | P value (Likelihood ratio test) | P value (Logrank test) |
Hemoglobin | 0.65 | 7×10−05 | 6×10−05 |
LDH | 0.68 | 0.0004 | 7×10−06 |
Wang_4genescore | 0.60 | 0.002 | 0.0007 |
ThirdLineTreatment | 0.56 | 0.006 | 0.002 |
AP | 0.63 | 0.008 | 0.001 |
VisceralMetastasis | 0.58 | 0.043 | 0.038 |
LeucocyteNr | 0.60 | 0.048 | 0.045 |
NLR | 0.56 | 0.15 | 0.095 |
Lymphocytes_percent | 0.58 | 0.3 | 0.3 |
SecondLineTreatment | 0.55 | 0.3 | 0.3 |
FirstLineTreatment | 0.51 | 0.4 | 0.4 |
BoneMetastasis | 0.51 | 0.4 | 0.4 |
Gleason | 0.53 | 0.6 | 0.6 |
Neutrophile_percent | 0.47 | >0.9 | >0.9 |
PSA | 0.57 | >0.9 | >0.9 |
B. Multivariate analysis of validation set II | Â | ||
 | P value (Wald’s test) |  |  |
Hemoglobin | 0.2 | Â | Â |
LDH | 0.3 | Â | Â |
Wang_4genescore | 0.03 | Â | Â |
ThirdLineTreatment | 0.002 | Â | Â |
AP | 0.9 | Â | Â |
visceralMets | 0.05 | Â | Â |
LeucocyteNr | 0.07 | Â | Â |